Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer

BACKGROUND: Gemcitabine (GEM) is the standard of care for pancreatic cancer. Unfortunately, median progression-free survival (PFS) is 2.2 months and overall survival (OS) is 5.65 months. Imatinib mesylate (IM) inhibits the Bcr-Abl tyrosine kinase and receptors for platelet-derived growth factor (PDG...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Moss, Rebecca A., Moore, Dirk, Mulchahy, Mary F., Nahum, Kenneth, Li, Hui, Moore, Katen, Fischer, Jane, Konduri, Srivani, Durivage, Henry, Poplin, Elizabeth
Format: Artigo
Idioma:Inglês
Publicat: International Society of Gastrointestinal Oncology 2010
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047035/
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars